Nephro_OK,
Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 CKD Receiving a Group II Gadolinium-Based Contrast Agent: A…
Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 CKD Receiving a Group II Gadolinium-Based Contrast Agent: A…
Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 CKD Receiving a Group II Gadolinium-Based Contrast Agent: A…
Cette question a une réponse, le risque est exceptionnelle, et ne faut pas priver le patient d’un examen IRM…